Tumor-targeted delivery of siRNA by self-assembled nanoparticles

Molecular Therapy

Volumn 16, Issue 1, 2008, Pages 163-169

  Li, Shyh Dar ^a   Chen, Yun Ching ^a   Hackett, Michael J ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOCARRIER; SIGMA OPIATE RECEPTOR; SMALL INTERFERING RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOTOXICITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR;

EID: 37549004351     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300323     Document Type: Article

References (46)

1. Jana, S, Chakraborty, C, Nandi, S and Deb, JK (2004). RNA interference: potential therapeutic targets. Appl Microbiol biotechnol 65: 649-657.
2. Li, SD and Huang, L (2006). Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13: 1313-1319.
3. Li, W and Szoka, FC Jr. (2007). Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 24: 438-449.
4. Grzelinski, M, Urban-Klein, B, Martens, T, Lamszus, K, Bakowsky, U, Hobel, S et al. (2006). RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17: 751-766.
5. Halder, J, Kamat, AA, Landen, CN Jr., Han, LY, Lutgendorf, SK, Lin, YG et al. (2006). Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12: 4916-4924.
6. Hu-Lieskovan, S, Heldel, JD, Bartlett, DW, Davis, ME and Triche, TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992.
7. Kim, WJ, Chang, CW, Lee, M and Kim, SW (2007). Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release 118: 357-363.
8. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015.
9. Medarova, Z, Pharn, W, Farrar, C, Petkova, V and Moore, A (2007). In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13: 372-377.
10. Pirollo, KF, Ralt A, Zhou, Q, Hwang, SH, Dagata, JA, Zon, G et al. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 67: 2938-2943.
11. Santel, A, Aleku, M, Keil, O, Endruschat, J, Esche, V, Fisch, G et al. (2006). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13: 1222-1234.
12. Schiffelers, RM, Ansari, A, Xu, J, Zhou, O, Tang, Q, Storm, G et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically, stabilized nanoparticle. Nucleic Acids Res 32: E149.
13. Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoom, DM et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23 709-717.
14. Takeshita, F, Minakuchi, Y, Nagahara, S, Honma, K, Sasaki, H, Hirai, K et al. (2005). Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182.
15. Wang, Y, Gao, S, Ye, WH, Yoon, HS and Yang, YY (2006). Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5: 791-796.
16. Yang, R, Yang, X, Zhang, Z, Zhang, Y, Wang, S, Cai, Z et al. (2007). Retraction. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther 14: 920.
17. de Wolf, HK, Snel, CJ, Verbaan, FJ, Schiffelers, RM, Hennink, WE and Storm, G (2007). Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 331: 167-175.
18. Li, SD and Huang, L (2006). Targeted delivery of antisense oligodeoxynudeotide and small interference RNA into lung cancer cells. Mol Pharm 3: 579-588.
19. Banerjee, R, Tyagi, P, Li, S and Huang, L (2004). Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 112: 693-700.
20. Li, SD and Huang, L (2006). Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci 1082: 1-8.
21. Brannon-Peppas, L and Blanchette, JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev S6: 1649-1659.
22. Jones, HE, Gee, IM, Hutcheson, IR, Knowiden, JM, Barrow, D and Nicholson, RI (2006). Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 13 (suppl. 1): S45-S51.
23. Nicholson, RI, Gee, JM and Harper, ME (2001). EGFR and cancer prognosis. Eur J Cancer 37 (suppl. 4): S9-S15.
24. Byers, LA and Heymach, JV (2007). Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8 (suppl. 2): S79-S85.
25. Dassonville, O, Bozec, A, Fischel, JL and Milano, G (2007). EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62: 53-61.
26. Sathomsumetee, S and Rich, JN (2006). New approaches to primary brain tumor treatment. Anticancer Drugs 17: 1003-1016.
27. Wong, SF (2005). Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27: 684-694.
28. Fan, QW and Weiss, WA (2005). RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 24: 829-837.
29. Kang, CS, Pu, PY, Li, YH, Zhang, ZY, Qiu, MZ, Huang, Q et al. (2005). An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J Neurooncol 74: 267-273.
30. Kang, CS, Zhang, ZY, Jia, ZF, Wang, GX, Qiu, MZ, Zhou, HX et al. (2006). Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther 13: 530-538.
31. Nozawa, H, Tadakuma, T, Ono, T, Sato, M, Hiroi, S, Masumoto, K et al. (2006). Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 97: 1115-1124.
32. Vollmann, A, Vomlocher, HP, Stempfl, T, Brockhoff, G, Apfel, R and Bogdahn, U (2006). Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. Int J Oncol 28: 1531-1542.
33. Wu, X, Deng, Y, Wang, G and Tao, K (2007). Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res 138: 56-63.
34. Zhang, M, Zhang, X, Bai, CX, Chen, J and Wei, MQ (2004). Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 25: 61-67.
35. Zhang, X, Chen, ZG, Choe, MS, Lin, Y, Sun, SY, Wieand, HS et al. (2005). Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269.
36. Li, S and Huang, L (1997). In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 4: 891-900.
37. Schwartz, DA, Quinn, TJ, Thorne, PS, Sayeed, S, Yi, AK and Krieg, AM (1997). CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 100: 68-73.
38. Braet, F and Wisse, E (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comp Hepatol 1 1.
39. Monsky, WL, Fukumura, D, Gohongi, T, Ancukiewcz, M, Weich, HA, Torchilin, VP et al. (1999). Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59: 4129-4135.
40. Pirollo, KF, Zon, G, Rait, A, Zhou, Q, Yu, W, Hogrefe, R et al. (2006). Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 17: 117-124.
41. Agrawal, S and Kandimalla, ER (2004). Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol 22: 1533-1537.
42. Robbins, MA and Rossi, JJ (2005). Sensing the danger in RNA. Nat Med 11: 250-251.
43. Gekeler, V, Gimmnich, P, Hofmann, HP, Grebe, C, Rommele, M, Leja, A et al. (2006). G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16: 83-93.
44. Wang, L, Smith, D, Bot, S, Dellamary, L, Bloom, A and Bot, A (2002). Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 110: 1175-1184.
45. Hornung, V, Guenthner-Biller, M, Bourquin, C, Ablasser, A, Schlee, M, Uematsu, S et al. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
46. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.